In vitro screening for compounds from Hypericum longistylum with anti-pulmonary fibrosis activity
| Autor: | Mengying Huang, Shuaishuai Liu, Yuanqiang Guo, Honggang Zhou, Yunqian Zhai, Xiangrong Cao, Shaoyan Gao, Xiaohe Li, Chunfeng Xie |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cell Survival
Pulmonary Fibrosis Clinical Biochemistry Drug Evaluation Preclinical Pharmaceutical Science Pharmacology 01 natural sciences Biochemistry Pathogenesis Transforming Growth Factor beta1 Idiopathic pulmonary fibrosis Mice Structure-Activity Relationship Drug Discovery Pulmonary fibrosis medicine Animals Luciferase MTT assay Smad3 Protein Cytotoxicity Fibroblast Molecular Biology Dose-Response Relationship Drug Molecular Structure 010405 organic chemistry Chemistry Plant Extracts Organic Chemistry Fibroblasts medicine.disease In vitro Antifibrinolytic Agents 0104 chemical sciences 010404 medicinal & biomolecular chemistry medicine.anatomical_structure Molecular Medicine Hypericum Signal Transduction |
| Zdroj: | Bioorganicmedicinal chemistry letters. 29(22) |
| ISSN: | 1464-3405 |
| Popis: | Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis and limited therapies, and transforming growth factor-β1 (TGF-β1) plays a central role in the pathogenesis of IPF. Here, we aimed to investigate the chemical constituents and biological activities of Hypericum longistylum and detect whether the isolated compounds inhibit the TGF-β1/Smad3 signaling pathway to identify candidate compounds for the treatment of pulmonary fibrosis. Fifteen compounds (1-15) were isolated from H. longistylum and their structures were elucidated on the basis of spectroscopic analyses. An in vitro MTT assay was used to test the effect of these fifteen compounds on fibroblast cytotoxicity and vitality. Furthermore, their bioactivities were screened using a TGF-β1/Smad3 pathway luciferase reporter in vitro. MTT screening found that compounds 1-15 had no deleterious effects on normal mouse lung fibroblasts and no significant inhibition of vitality. Luciferase assay showed that compounds 14 and 15 could significantly inhibit the TGF-β1/Smad3 pathway with the inhibition rates of 67.92% and 93.10%, respectively. Both compounds can be used as lead compounds for structural modification and optimization to obtain more drug candidates for the treatment of pulmonary fibrosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect